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ABSTRACT:  The hepatoprotective effect of Annona muricata and Polyalthia cerasoides 
(Annonaceae) were monitored by estimating the serum transaminases (SGOT and SGPT), serum 
alkaline phosphatase (SALP), liver and brain lipid peroxidation (LOP) and their total protein 
content.  Both drugs at a dose of 100 µg/kg significantly prevented the increase in serum 
transaminases, SALP, liver and brain LOP and decrease in liver and brain total protein content 
following carbontetrachloride (CCl) induced hepatoxicity in albino rats. 
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INTRODUCTION 
 
There is a progressive increase in the 
incidence of hepatic damage mainly due to 
the viral infection, hepatotxic chemicals 
(alcohol), peroxides, toxin in food, 
pharmaceuticals, environmental pollutants 
and xenobiotics.  There is hardly any 
remedy available in the modern system of 
medicine, including corticosteroids and 
immunosuppressive agents which bring 
about symptomatic relief supporting only 
the process of healing or liver regeneration 
(Handa et al., 1986; Hikino and Kiso, 1988).  
Hence increasing attention is being given to 
plants recommended for the treatment of 
hepatic disorders in the traditional system of 
medicine.  A decoction of both these plant 
drugs are prescribed by practitioners in the 
Indian system of medicine for the treatment 
of liver disorders.  In this context, we have 
assessed the hepatoprotective activity of 
alcoholic  extracts of A.muricata an 
P.cerasoides against carbontetrachloride 
induced hepatotoxicity as its involvement in 
free radical mediated reactions to produce 
hepatic injury is very well established. 
 
MATERIALS AND METHODS 
Plant material and extraction 
 
The stembarks of A.muricata and 
P.cerasoides were procured from Tirunelveli 
district (Tamilnadu, India) and authenticated 
by Dr. V. Chelladurai, Survey of Medicinal 
Plant Unit, Government Siddha Medical 
College, Tirunelveli.  Voucher specimen 
PP/PH/01/95 and PP/PH/02/95 are preserved 
in the Department of Pharmaceutics, 
Banaras Hindu University, Varanasi.  The 
plant materials were dried, reduced to 
moderately coarse powder and then 
materials (500 gm each) were defatted with 
petroleum ether (60-80
0C, 31, 18hrs) in a 
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soxhlet and thoroughly extracted with 
ethanol (95%, 21-36 hr) the ethanolic extract 
was dried (48gm and 24.2 gm respectively) 
in a heated vacuum desiccator and made into 
a suspension in water and propylene glycol 
(4:1) containing Tween 80 (0.08%) at the 
concentration of 200 mg/ml. 
 
Animals 
 
Adult albino rats (Charles- Foster strain, 
150±20 gm, b.w.) were kept in 
polypropylene cages (3 in each cage) at an 
ambient temperature of 25
0±2
0C with 55-
65% relative humidity and 12±1 hr dark – 
light cycle.  These animals had free access 
to water and normal laboratory diet (Lipton 
India Ltd.). 
 
Hepatoprotective Activity 
 
Animals were divided into 4 groups, group I 
and II served as control and 
carbontetrachloride control, received the 
vehicle (Water : propylene glycol : 4:1) by 
gastric intubation, once daily for 7 days.   
Group III and IV were given, 1 ml each of 
suspension of alcoholic extract of A. 
muricata  and P.cerasoides  at a dose of 100 
mg/kg, b.w., once daily for 7 days through 
gastric intubation. 
 
On the 8
th day, one hour after the 
administration of the last dose of drug, the 
animals of group II,III,IV were given an 
intraperitoneal injection of 
carbontetrachloride 0.5 ml/kg, b.w.  All the 
animals were then fasted for 24 hours after 
which they were anasesthetized and the 
blood was collected by cardiac puncture.   
The liver and brain were quickly dissected 
out and stored at -20
0c.  The blood samples 
were allowed to coagulate at room 
temperature for one hour.  Serum was 
separated by centrifugation at 4
0c, 12,000 
rpm for 5 minutes.  
 
Biochemical Studies 
 
The activity of serum glutamic oxaloacetic 
transminase (SGOT, AST) and glutamic 
pyruvic transaminase (SGPT, ALT) were 
estimated according to the method of 
Reitman and Frankel (1957).  The serum 
alkaline phosphatase (SALP) levels were 
determined by the method of Bessey et al. 
(1946).  Liver and brain lipid peroxidation 
level were estimated by the method of 
Ohkawa et al. (1979) and the total protein 
content in liver and brain were estimated by 
Lowry et al. (1951). 
 
RESULTS AND DISCUSSION 
 
The results are given in the Tables 1,2 and 3.  
The hepatotoxicity of CCl4 has been shown 
to depend on its metabolism by cytochrome 
P-450 to produce free radicals which can 
initiate the damaging process through 
enhancement of membrane 
lipidperoxidation, covalent binding to 
macromolecules, protein and metabolic 
enzymes (Poli, 1993).  Carbontetrachloride 
treated group (hepatotoxin only Group II) 
had shown leakage of transaminases 
culminating in the liver injury.  In liver and 
brain, there was a significant increase in 
LPO levels whereas their protein level 
showed a significant decrease suggesting a 
secondary mechanism involved in CCl4 
metabolism capable of affecting distant loci.  
It is very well established that the CCl4 
induced hepatotoxicity can be divided into 
three sequences viz. initial events, secondary 
evoked mechanism and end-stage 
pathological consequences, finally altering 
physiochemical properties of the membranes 
leading to its functional and structural 
disruption (Recknagel, 1983; Feher et al., 
1986). 
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The alcoholic extract of A.muricata and 
P.cerasoides (Tables 1 & 2) have afforded 
and overall protection against CCl4 induced 
toxicity, the activity being slightly less in the 
case of P.cerasoides.  LPO (in both liver and 
brain) and SALP levels were reduced 
significantly by both drugs (Tables 1 & 2) 
suggesting that the plant drug scavenges free 
radicals produced by CCl4 metabolism 
which could be the possible mode of action 
of these drugs as hepatoprotective agents.   
The percentage protection afforded by the 
two drugs against increase in SGOT, SGPT, 
SLP, liver and brain LPO levels and 
decrease in liver and brain protein levels are 
given in Table 3.  All these data suggest that 
the plant drugs possess possible 
antihepatotoxic activity which are in tune 
with the fact that these drugs are prescribed 
by traditional medical practitioners ion 
Indian to be administered in form of 
decoction against liver disorders. 
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TABLE 1 
Effect of drug treatment on serum transaminase level 
 
Sl. 
No. 
Groups SGPT  (ALT) 
U/ml 
SGOT (AST) 
U/ml 
Alkaline 
Phosphatase 
(KA units) 
 
1 Control  35.56±6.12  (10)  118.60±17.80(10)  14.57±1.40(7) 
2  Carbon Tetrachloride control  1700.00±114.82 (10)  2010.00±67.47(10)  74.77±9.98(7) 
3 A.muricata  treated  765.00±91.86(7)
a 1243.30±115.75(7)
a 26.19±1.81(7)
a 
4  P.cerasoides treated  1197.14±118.92 (7)
b 1425.71±196.33(7)
c 40.71±3.87(7)
b 
aP<0.001; 
bP<0.01; 
cP<0.02 when compared to carbon tetrachloride control. 
Figures in paranthesis indicate the number of observations. 
 
TABLE 2 
Effect of drug treatment on protein and lipid peroxidation levels in liver and brain 
 
Protein mg/g tissue  Lipid peroxidation MDA 
nmole/mg 
Sl.  
No. 
Group 
Liver Brain  Liver  Brain 
1 Control  (7)  117.07±6.81 37.49±1.01 422.37±28.0  178.34±14.46
2 Carbon  tetrachloride 
Control (7) 
62.80±3.29 18.39±0.88 889.20±22.48 634.70±25.27
3  A.muricata treated (7)  101.70±4.02
a 28.20±1.71
a 492.00±18.72
a 210.50±29.71
a
4  P.cerasoides treated (7)  98.20±3.97
a 22.40±2.01 639.00±29.97
a 357.00±30.71
a
aP<0.001 when compared to carbon tetrachloride control. 
 
TABLE 3 
Mean values of percentage production of drug treatment against CCl4 challenge 
 
Lipid peroxidation 
nmoles/mg tissue 
Total Protein   
mg/g tissue 
Treatment 
Group 
SGPT 
U/ml 
SGOT
U/ml 
SALP 
KA units 
Liver  Brain Liver Brain 
A.muricata 
treated 
56.20  40.54  80.70  85.09  92.30 71.68 33.71 
P.cerasoides 
treated (7) 
30.21  30.89  56.58  53.60  56.91 65.23 13.79 
                                   Value from drug treatment – Value from CCl4 treated 
 % Mean protection =                                                                                          X100 
                                   Value from vehicle treated – Value from CCl4 treated     
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